LUND, SWEDEN -- November 29, 2007 -- AstraZeneca announced today that it has received Swedish Medical Products Agency (MPA) approval for use of Nexium (esomeprazole) in children aged 1-11 years with gastroesophageal reflux disease (GERD) in the reference member state of Sweden, with other European Union nations expected to follow.
